Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 4/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925009 | 0.86 | TAAR1 (0.64) | MPOSLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL11942564 | 0.83 | ALOX5 (0.44) | MPOSLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL25143184 | 0.82 | MPO (0.56) | MPOSLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL13850100 | 0.81 | ALOX5 (0.47) | MPOSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19658854 | 0.81 | TYR (0.44) | MPOSLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL14154 | 0.81 | TAAR1 (0.74) | MPOTAAR1 | |
| SCHEMBL17354504 | 0.80 | MPO (0.50) | MPOSLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL6192614 | 0.79 | MPO (0.50) | MPOSLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL17188320 | 0.79 | ALDH1A1 (0.40) | MPOSLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL10110932 | 0.79 | TAAR1 (0.71) | MPOTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | MPO 1/4885SLC6A2 3776/4885SLC6A4 4116/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | MPO 1/4885SLC6A2 3776/4885SLC6A4 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.